STAB Stock Overview
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Statera Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0006 |
52 Week High | US$0.038 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -96.39% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
STAB | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -5.0% | -3.5% |
1Y | -96.4% | -1.7% | 20.2% |
Return vs Industry: STAB underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: STAB underperformed the US Market which returned 20.9% over the past year.
Price Volatility
STAB volatility | |
---|---|
STAB Average Weekly Movement | 0% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: STAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine STAB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Mike Handley | www.staterabiopharma.com |
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.
Statera Biopharma, Inc. Fundamentals Summary
STAB fundamental statistics | |
---|---|
Market cap | US$43.55k |
Earnings (TTM) | -US$91.83m |
Revenue (TTM) | US$3.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs STAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
STAB income statement (TTM) | |
---|---|
Revenue | US$3.69m |
Cost of Revenue | US$1.10m |
Gross Profit | US$2.59m |
Other Expenses | US$94.42m |
Earnings | -US$91.83m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did STAB perform over the long term?
See historical performance and comparison